PB Mental Health Guidelines from NICE
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals
 QUICK SEARCH:   [advanced]


     


Psychiatric Bulletin (1998) 22: 675-677. doi: 10.1192/pb.22.11.675
© 1998 The Royal College of Psychiatrists
This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Milton, J.
Right arrow Articles by Buckley, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Milton, J.
Right arrow Articles by Buckley, A.

Hidden high-dose antipsychotic prescribing: effects of p.r.n. doses

John Milton, Senior Registrar in Psychiatry*

Nottingham Healthcare NHS Trust, Duncan Macmillan House, Porchester Road, Nottingham NG3 6AA

John Lawton, Senior Pharmacist and Mark Smith

Clinical Audit Department, Nottingham Healthcare NHS Trust, Nottingham

Ann Buckley, Senior Registrar in Psychiatry

South Birmingham Mental Health NHS Trust, Mindleson Way, Birmingham

* Correspondence

Aims and method The Royal College of Psychiatrists' Consensus Statement on ‘The use of high-dose antipsychotic medication’ suggests only fully qualified psychiatrists (MRCPsych) should recommend the prescribing of high-dose antipsychotic treatment. We observed changes in anti-psychotic prescribing in two surveys of psychiatric in-patients conducted eight and 32 months after publication of the Consensus Statement.

Results Overall mean chlorpromazine equivalent doses of antipsychotic drugs reduced between the surveys. When p.r.n. (as required) prescribing (usually done by junior doctors) is included, mean potential doses and numbers of patients who might receive ‘high-doses’ increases substantially, although the reduction between surveys in total mean dose and proportion of patients on high-dose antipsychotic medication is preserved, and the actual use of p.r.n. medication was low (4–5% of p.r.n. prescriptions).

Clinical implications We recommend the development of local guidelines for junior staff concerning antipsychotic drug prescribing, regular monitoring of p.r.n. medication by consultants, and pharmacists' involvement in reviews of patients prescribed high-dose antipsychotic medication.




This article has been cited by other articles:


Home page
Adv. Psychiatr. Treat.Home page
D. S. Baldwin and N. Kosky
Off-label prescribing in psychiatric practice
Advan. Psychiatr. Treat., November 1, 2007; 13(6): 414 - 422.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1998 The Royal College of Psychiatrists.